Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3012% below fair value
$8.32−0.18 (-2.12%)
Close on Nov 17, 2026Market cap $560.27MP/E –Yield –
Ginkgo Bioworks cash
Cash and short-term investments held at the end of each period.
Ginkgo Bioworks's cash was $84.54M at Jun 30, 2026. For fiscal 2025 it was $422.62M, down 24.7% from the year before. The highest annual figure on record is $1.55B in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $422.62M | -24.7% |
| FY2024 | Dec 31, 2024 | $561.57M | -40.5% |
| FY2023 | Dec 31, 2023 | $944.07M | -28.3% |
| FY2022 | Dec 31, 2022 | $1.32B | -15.1% |
| FY2021 | Dec 31, 2021 | $1.55B | +307.0% |
| FY2020 | Dec 31, 2020 | $380.80M | -23.1% |
| FY2019 | Dec 31, 2019 | $495.29M | +138.8% |
| FY2018 | Dec 31, 2018 | $207.39M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $84.54M | -84.9% |
| Q1 FY2026 | Mar 31, 2026 | $143.86M | -55.8% |
| Q4 FY2025 | Dec 31, 2025 | $422.62M | -24.7% |
| Q3 FY2025 | Sep 30, 2025 | $495.48M | -19.6% |
| Q2 FY2025 | Jun 30, 2025 | $559.36M | -23.4% |
| Q1 FY2025 | Mar 31, 2025 | $325.26M | -61.3% |
| Q4 FY2024 | Dec 31, 2024 | $561.57M | -40.5% |
| Q3 FY2024 | Sep 30, 2024 | $616.21M | -41.3% |
| Q2 FY2024 | Jun 30, 2024 | $730.37M | -34.0% |
| Q1 FY2024 | Mar 31, 2024 | $840.44M | -30.3% |
| Q4 FY2023 | Dec 31, 2023 | $944.07M | -28.3% |
| Q3 FY2023 | Sep 30, 2023 | $1.05B | -19.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.11B | -19.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.21B | -19.2% |
| Q4 FY2022 | Dec 31, 2022 | $1.32B | -15.1% |
| Q3 FY2022 | Sep 30, 2022 | $1.30B | -25.1% |
| Q2 FY2022 | Jun 30, 2022 | $1.38B | +483.8% |
| Q1 FY2022 | Mar 31, 2022 | $1.49B | +384.5% |
| Q4 FY2021 | Dec 31, 2021 | $1.55B | +307.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.74B | +269.2% |
| Q2 FY2021 | Jun 30, 2021 | $235.89M | -52.4% |
| Q1 FY2021 | Mar 31, 2021 | $308.13M | +48.6% |
| Q4 FY2020 | Dec 31, 2020 | $380.80M | – |
| Q3 FY2020 | Sep 30, 2020 | $471.06M | – |
| Q4 FY2019 | Dec 31, 2019 | $495.29M | – |
| Q4 FY2018 | Dec 31, 2018 | $207.39M | – |
See a number that looks wrong?